P2191
Poly(D,L-lactide-co-glycolide)
lactide:glycolide (50:50), mol wt 30,000-60,000
Sinónimos:
LACTEL® B6010-2, PLGA
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula lineal:
[C3H4O2]x[C2H2O2]y
UNSPSC Code:
12352211
PubChem Substance ID:
NACRES:
NA.25
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlefeed ratio
lactide:glycolide (50:50)
Quality Level
mol wt
30,000-60,000
storage temp.
−20°C
SMILES string
OCC(O)=O.CC(O)C(O)=O
InChI key
XBBVURRQGJPTHH-UHFFFAOYSA-N
General description
Poly(D,L-lactide-co-glycolide) is a biodegradable and biocompatible polymer, which is used for drug delivery. It is used to treat rheumatoid arthritis, ulcerative colitis, Crohn′s disease, inflammatory lung diseases and ophthalmic inflammatory disorders. Poly(D,L-lactide-co-glycolide) functions as a potential cancer therapeutic target.
Application
Poly(D,L-lactide-co-glycolide) has been used to raise and sustain an increased lactate monomer level in the gel at a concentration relevant to dermal wounds.
Features and Benefits
Controlled release of bioactive agents, sutures and bioabsorbable implantable devices.
Physical form
Biocompatible, biodegradable polymer.
Legal Information
Lactel is a registered trademark of Evonik Corp
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Characterization of biodegradable poly (D, L-lactide-co-glycolide) polymers and microspheres
Hausberger AG and DeLuca PP
Journal of Pharmaceutical and Biomedical Analysis, 13(6), 747-760 (1995)
PLGA-based nanoparticles: an overview of biomedical applications
Danhier F, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 161(2), 505-522 (2012)
Habibun Nabi et al.
Parasitology research, 116(1), 359-370 (2016-10-28)
Toxoplasmosis is one of the most common zoonotic protozoal diseases. Recent advances in biotechnology have produced recombinant protein, which are immunogenic, and progress in nano-pharmaceutics has generated encapsulated protein in nanospheres, which are suitable for vaccine delivery. DNA was extracted